General Partner Inc. Takes $113,000 Position in Novo Nordisk A/S (NYSE:NVO)

General Partner Inc. acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the first quarter, Holdings Channel.com reports. The fund acquired 880 shares of the company’s stock, valued at approximately $113,000.

Other hedge funds also recently made changes to their positions in the company. Barclays PLC grew its position in shares of Novo Nordisk A/S by 28.5% during the third quarter. Barclays PLC now owns 17,694 shares of the company’s stock worth $1,609,000 after buying an additional 3,926 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Novo Nordisk A/S by 245.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 68,477 shares of the company’s stock worth $6,227,000 after purchasing an additional 48,678 shares during the period. Fiera Capital Corp boosted its holdings in Novo Nordisk A/S by 237.7% in the third quarter. Fiera Capital Corp now owns 6,372 shares of the company’s stock worth $579,000 after purchasing an additional 4,485 shares during the period. Rhumbline Advisers boosted its holdings in Novo Nordisk A/S by 121.6% in the third quarter. Rhumbline Advisers now owns 59,322 shares of the company’s stock worth $5,395,000 after purchasing an additional 32,551 shares during the period. Finally, William Blair Investment Management LLC boosted its holdings in shares of Novo Nordisk A/S by 99.6% during the third quarter. William Blair Investment Management LLC now owns 61,795 shares of the company’s stock valued at $5,620,000 after acquiring an additional 30,841 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Monday. Argus boosted their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Finally, The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $145.67.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded up $0.06 during midday trading on Tuesday, hitting $140.43. The company’s stock had a trading volume of 1,242,079 shares, compared to its average volume of 4,486,418. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The stock’s 50-day moving average price is $131.65 and its 200-day moving average price is $120.89. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $144.50. The company has a market capitalization of $630.18 billion, a PE ratio of 48.40, a price-to-earnings-growth ratio of 1.48 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The firm had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. Analysts anticipate that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.